These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28817445)

  • 21. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
    Hanna KS
    Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
    Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
    Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
    Davick JJ; Wick MR; Gru AA
    Melanoma Res; 2017 Aug; 27(4):383-386. PubMed ID: 28574977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab.
    Wahid M; Akhter N; Jawed A; Dar SA; Mandal RK; Lohani M; Areeshi MY; Khan S; Haque S
    Crit Rev Oncol Hematol; 2017 Mar; 111():1-6. PubMed ID: 28259284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
    J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on pembrolizumab in the treatment of advanced melanoma.
    Rajakulendran T; Adam DN
    Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
    Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.